Cardiovascular Health

GHRP-6 The original growth hormone releasing peptide, developed in 1984. Researchers studying the GH axis often compare GHRP-6 with its successors as a reference compound. View research notes → NAD+ One of the most-studied molecules in longevity science. NAD+ is a coenzyme rather than a peptide, but is widely tracked alongside research peptides for its role in aging, cellular repair, and metabolic function. View research notes → Retatrutide Retatrutide (LY3437943) is a triple hormone receptor agonist developed by Eli Lilly, simultaneously activating the GIP, GLP-1, and glucagon receptors. Phase 2 trials showed approximately 24% mean body weight reduction at 48 weeks, the largest reported for any obesity drug to date. View research notes → Semaglutide Semaglutide has more large-scale human trial data behind it than almost any other peptide women research, and most of what's written about it still ignores the questions women actually ask: what it does to weight at midlife, what the PCOS research shows, and what a fair per-mg price looks like. Here is the evidence, the FDA picture, and the pricing, plainly. View research notes → SS-31 (Elamipretide) SS-31, also known as elamipretide or MTP-131, is a mitochondria-targeted tetrapeptide that homes to the inner mitochondrial membrane and stabilizes cardiolipin. Research spans cardiac aging, hypertensive cardiomyopathy, and skeletal muscle decline. View research notes → TB-500 TB-500 is a synthetic peptide fragment studied for tissue repair, wound healing, and cardiac regeneration. Here is what the published evidence looks like. View research notes → Tirzepatide Tirzepatide targets two incretin receptors at once, and in the trial record that has meant the largest weight reductions yet measured in a drug study, results that matter to the women comparing it against semaglutide for midlife metabolic research. Here is what the evidence actually shows, including the heart failure finding that is especially relevant to women. View research notes → VIP (Vasoactive Intestinal Peptide) VIP is a twenty-eight amino acid peptide the body makes on its own, isolated from gut tissue in 1970. Its synthetic form is called aviptadil, and it has more real clinical trial data behind it than most research peptides. Nearly all of that data comes from routes and conditions that have nothing to do with what people buy it for. View research notes →